tiprankstipranks
Trending News
More News >

Solvonis Therapeutics Announces 2025 AGM Details Amidst Clinical Progress

Story Highlights
  • Solvonis Therapeutics is a biopharmaceutical company targeting addiction and mental health disorders.
  • The company announced its 2025 AGM, highlighting its commitment to transparency and clinical progress.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Solvonis Therapeutics Announces 2025 AGM Details Amidst Clinical Progress

Don’t Miss TipRanks’ Half-Year Sale

Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an announcement.

Solvonis Therapeutics plc has announced the posting of its 2025 Annual General Meeting notice and proxy form to shareholders, with the meeting scheduled for 27 June 2025 in London. This announcement underscores Solvonis’s ongoing commitment to transparency and shareholder engagement as it progresses its clinical programs, which include a Phase 3 trial for severe Alcohol Use Disorder and a preclinical PTSD program. The company’s strategic focus on high-burden neuropsychiatric conditions positions it to potentially impact the treatment landscape significantly.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for addiction and mental health disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis is advancing a pipeline of repurposed and novel compounds targeting neuropsychiatric conditions. The company’s lead programs address Alcohol Use Disorder and Post-Traumatic Stress Disorder, with key assets in various trial phases across Europe, the UK, and the US.

Average Trading Volume: 14,588,439

Technical Sentiment Signal: Sell

Current Market Cap: £7.83M

Learn more about SVNS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1